Background: Following primary vaccination of adults P65 years of age with 23-valent pneumococcal polysaccharide vaccine (PPSV23), immune responses increase and thereafter appear to decrease over time. With increased life expectancy worldwide, revaccination with PPSV23 may be required for continued protection of the elderly population against pneumococcal disease. The present study evaluated the immunogenicity and safety of revaccination with PPSV23 in the Japanese elderly. Methods: Depending on prior history of PPSV23 vaccination, adults aged P70 years were given a first dose (primary group; N = 81) or second dose (revaccination group; N = 161, at least 5 years after first dose) of PPSV23 intramuscularly. Subjects were matched for gender, age, and number and type of comorbidity across both groups. Blood samples were collected before and 4 weeks postvaccination to measure serotype-specific immunoglobulin G (IgG) concentrations and opsonophagocytic killing activity (OPA) antibody titers to serotypes included in the vaccine. Injection-site and systemic adverse events (AEs) were collected for 14 days postvaccination. Results: Baseline serotype-specific IgG geometric mean concentrations (GMCs) and OPA geometric mean titers (GMTs) were generally higher in subjects with a prior history of PPSV23 vaccination than in PPSV23-naïve subjects. The levels of IgG GMCs and OPA GMTs after revaccination were generally comparable to those observed after primary vaccination. Incidences of systemic AEs were comparable between the 2 groups. Although incidences of injection-site AEs were higher following revaccination than primary vaccination, the difference was not clinically significant as most AEs were mild to moderate in intensity and resolved within 5 days after revaccination without treatment. Conclusion: Revaccination with PPSV23 was well tolerated and associated with increases in serotype-specific IgG concentrations and OPA titers in the elderly who received a prior PPSV23 dose at least 5 years before. Revaccination with PPSV23 can be safely implemented in the elderly for continued prevention against pneumococcal disease. Clinical trial registry number: NCT02260882
Worldwide, adults P65 years of age are at high risk for pneumococcal disease. The risk is further increased for those with underlying illnesses such as chronic heart disease, chronic lung disease, and diabetes mellitus [1, 2] Abbreviations: AE, adverse event; CI, confidence interval; GMC, geometric mean concentration; GMFR, geometric mean fold rise; GMT, geometric mean titer; IgG, immunoglobulin G; IPD, invasive pneumococcal disease; MOPA, multiplexed OPA; OPA, opsonophagocytic killing activity; Pn ECL, pneumococcal electrochemiluminescence; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.
in adults including the elderly population [3] [4] [5] [6] [7] [8] [9] [10] , and PPSV23 is indicated for the prevention of pneumococcal disease in adults P50 years of age in many countries worldwide. In 2012-2013, serotypes most frequently associated with invasive pneumococcal disease (IPD) in Japanese adults included serotypes 3 (18.5%), 22F (7.9%), 14 (7.5%), 19A (7.5%), 6C (7.5%), and to a lesser extend serotypes 6B, 10A and 23F. Based on these results, the coverage rate afforded by PPSV23 for all IPD cases was 72.2% [11] . In October 2014, Japan introduced PPSV23 in the national immunization program for the prevention of pneumococcal disease for elderly individuals aged P65 years. Recently a 13-valent pneumococcal conjugate vaccine (PCV13) was approved in Japan for the prevention of pneumococcal disease in adults aged P65 years, but it is not included in the national immunization program.
Following PPSV23 vaccination, serotype-specific immunoglobulin G (IgG) concentrations and opsonophagocytic killing activity (OPA) titers increase and then decline over time, though these generally remain above pre-vaccination levels after 5 years [12] [13] [14] . Since decreases in serotype-specific IgG concentrations and OPA titers may lead to an increased risk of pneumococcal disease, revaccination may be required in order to provide continued protection with increasing age.
Over the past 40 years, Japan has become an ageing society; in 2010, the average life expectancy after the age of 65 was 18.74 and 23.80 years for men and women, respectively [15] . The need for revaccination with PPSV23 in the Japanese elderly individuals is expected to increase in the near future. PPSV23 revaccination in adults aged P65 years who received their first dose of PPSV23 at least 5 years before is recommended by the Japanese Association for Infectious Diseases [16] . Ohshima et al. evaluated the safety and immunogenicity of a second dose of PPSV23 in 40 elderly patients with chronic lung disease [17] . The present study was conducted in order to confirm the acceptable safety and immunogenicity profiles of PPSV23 revaccination in a large cohort of the Japanese elderly subjects, and to provide further evidence of the value of revaccination in clinical practice.
Methods

Overall study design
This was a non-randomized, open-label, multicenter study conducted at 5 sites (3 general hospitals and 2 clinics) between November 2014 and May 2015 to evaluate the immunogenicity and safety of revaccination with PPSV23 in the Japanese elderly population. Subjects were enrolled into one of the following groups in a 2:1 ratio: revaccination group (subjects who had a confirmed record of prior PPSV23 vaccination at least 5 years before study enrollment) or primary vaccination group (subjects with no prior history of PPSV23 vaccination). Characteristics such as age, gender and number and type of comorbidity (i.e., chronic heart disease: hypertension, angina pectoris and atrial fibrillation; chronic lung disease: asthma, chronic bronchitis and chronic obstructive pulmonary disease; diabetes mellitus) were matched between the two groups. Immunocompromised subjects, those receiving immunosuppressive therapy such as systemic corticosteroids, those with a history of vaccination with pneumococcal conjugate vaccine, those with a history of pneumococcal disease (positive culture from blood or other normally sterile site) and those who were febrile (defined as an oral temperature P37.5°C) within 24 h before PPSV23 vaccination were excluded from the study. 
Study objectives
The primary immunogenicity objective was to demonstrate that serotype-specific IgG GMCs to serotypes 3, 6B, and 23F measured 4 weeks after revaccination with PPSV23 were statistically greater than those measured immediately before revaccination (baseline); these serotypes were selected because they were most prevalent in Japanese adults with IPD, associated with 16.4% (serotype 3), 14.9% (serotype 6B), and 7.6% (serotype 23F) of all IPD cases during 2010-2011 [11] . Overall, serotype-specific IgG GMCs to 14 serotypes and serotype-specific OPA GMTs to 6 serotypes were measured immediately before and after primary vaccination or revaccination with PPSV23. The safety objective was to assess injection-site and systemic adverse events (AEs) after vaccination with PPSV23 in the primary vaccination and revaccination groups.
Measurements
Blood samples were collected before and 4 weeks following vaccination with PPSV23, and serum samples were stored at À20°C until used for testing. For serotype-specific IgG, antibody concentrations of 14 serotypes included in PPSV23 (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F) were measured using pneumococcal electrochemiluminescence (Pn ECL) assay [18] . Moreover, IgG concentration for serotype 6A, which is not included in PPSV23, was measured to assess possible cross-reactivity afforded by an immune response to serotype 6B, which is included in PPSV23. OPA was measured for 6 serotypes (3, 4, 6B, 14, 22F, and 23F) using multiplexed OPA (MOPA) assay [19] . The Pn ECL and OPA testing were performed at PPD Vaccines and Biologics Laboratory (Wayne, PA, USA) and at the University of Alabama (Birmingham, AL, USA), respectively.
Injection-site and systemic AEs occurring within 14 days postvaccination were collected. Deaths and other vaccine-related serious adverse events (SAEs) were recorded throughout the study. All subjects were asked to record any injection-site reaction and daily body temperature (oral method) in a vaccine diary for 5 consecutive days postvaccination. Causal relationship between the reported AEs and receipt of PPSV23 was assessed by the study investigators.
Statistical analysis
For the analyses of immunogenicity in the revaccination group, a one-sample t-distribution was used to obtain the mean and 95% confidence interval (CI) of changes in IgG GMCs from baseline (before revaccination) to 4 weeks after revaccination. Subsequently, the mean and 95% CI were back transformed to calculate the corresponding point estimate and 95% CI for geometric mean fold rise (GMFR). The statistical success criterion for demonstrating greater IgG GMCs at 4 weeks after vaccination was that the lower bound of the two-sided 95% CI for GMFR was >1.0 for all three serotypes (3, 6B, and 23F). For immunogenicity analyses for other serotypes in the primary vaccination and revaccination groups, IgG GMCs and OPA GMTs were calculated in a similar manner at baseline and 4 weeks after vaccination.
The safety was evaluated based on solicited injection-site AEs (pain, erythema, and swelling) occurring from Days 1 to 5 after vaccination, fever (P37.5°C, oral temperature) occurring from Days 1 to 5 after vaccination, and any other injection site and systemic AEs occurring from Days 1 to 14 after vaccination.
Ethical conduct
The present study was conducted in accordance with the principles of Good Clinical Practice. The protocol and informed consent forms were reviewed and approved by the institutional review board at each study site. Written informed consent was obtained from all subjects before initiation of any protocolspecified study procedure.
Results
Baseline characteristics and disposition of subjects
A total of 242 subjects (161 in the revaccination group and 81 in the primary vaccination group) received a single dose of PPSV23. All subjects completed the study. In the revaccination group, 94 subjects (58.4%) were women, and the mean age was 78.8 years. Among revaccinated subjects, a total of 127 (78.9%), 53 (32.9%), and 33 (20.5%) subjects had underlying chronic heart disease, chronic lung disease and diabetes mellitus, respectively, and 63 subjects (39.1%) had at least two comorbidities. Only 19 revaccinated subjects (11.8%) had none of these major comorbidities. Subject baseline characteristics were similar in both vaccination groups with regard to gender, age, and presence of comorbidities. The median time interval between primary vaccination and revaccination with PPSV23 in the revaccination group was 7 years (range, 5-11) ( Table 1) .
Immunogenicity
Serotype-specific IgG antibody
In the revaccination group, serotype-specific IgG GMCs to serotypes 3, 6B, and 23F measured 4 weeks after revaccination with PPSV23 were 0.49, 2.10, and 3.34 lg/mL, respectively. The corresponding IgG GMFRs (95% CIs) for serotypes 3, 6B, and 23F were 2.72 (2.35, 3.14), 2.27 (2.02, 2.55), and 2.40 (2.12, 2.72), respectively. IgG GMCs for serotypes 3, 6B, and 23F measured 4 weeks after revaccination were significantly greater (P < 0.001) than those measured immediately before revaccination, as the lower bounds of the two-sided 95% CIs for IgG GMFR were >1.0 for all three serotypes (Table 2) .
Baseline IgG GMCs to 14 serotypes included in PPSV23 were higher in the revaccination group than in the primary vaccination group. Serotype-specific IgG GMCs to each of the 14 serotypes were significantly higher at 4 weeks after vaccination with PPSV23 than those at baseline in both vaccination groups, although IgG GMCs at 4 weeks after vaccination with PPSV23 varied by serotypes in both groups. IgG GMFRs at 4 weeks after vaccination were significantly lower in the revaccination group than in the primary vaccination group (nominal P < 0.05). Only the IgG GMC for serotype 19A measured at 4 weeks after vaccination with PPSV23 in the revaccination group was significantly lower than that observed in the primary vaccination group (nominal P = 0.039), but levels of serotype-specific IgG GMCs for the other 13 serotypes at 4 weeks after vaccination with PPSV23 were numerically comparable in both primary vaccination and revaccination groups (Table 2 and Fig. 1 ).
Serotype-specific functional OPA
Baseline serotype-specific OPA GMTs were greater in the revaccination group than in the primary vaccination group. Serotype-specific OPA GMTs to each of the 6 serotypes tested by MOPA assay were significantly greater at 4 weeks after vaccination with PPSV23 than those at baseline in both vaccination groups. Likewise, OPA GMFRs at 4 weeks after vaccination were significantly lower in the revaccination group than in the primary vaccination group (nominal P < 0.05). Only the OPA GMT for serotype 4 measured at 4 weeks after vaccination with PPSV23 in the revaccination group was significantly lower than that observed in the primary vaccination (nominal P = 0.005), but levels of serotype-specific OPA GMTs for the other 5 serotypes measured at 4 weeks after vaccination with PPSV23 were numerically comparable in both primary vaccination and revaccination groups (Table 3 and Fig. 1 ).
Safety
Incidence rates of injection-site and systemic AEs occurring after PPSV23 vaccination in each vaccination group are summarized in Table 4 . More subjects in the revaccination group reported at least one injection-site AE than those in the primary vaccination group (70.2% and 50.6%, respectively). Severe injection-site pain, erythema and swelling of >10 cm (4 in.) were reported by 3.7%, 6.2%, and 4.3%, respectively, in the revaccination group, and no subject reported a severe injection-site AE in the primary vaccination group. No differences were observed between the 2 vaccination groups in the incidence rates of systemic AEs: 26.1% in the revaccination group and 19.8% in the primary vaccination group. Fever P37.5°C to <38.0°C, P38.0°C to <38.5°C, and P38.5°C were reported by 4.3% (7/161), 1.9% (3/161), and 0.6% (1/161), respectively in the revaccination group, and fever P37.5°C to <38.0°C was reported by 1.2% (1/81) in the primary vaccination group. Other common systemic AEs in both vaccination groups were diarrhoea, malaise, nasopharyngitis, and dizziness. No deaths or vaccine-related AEs leading to study discontinuation occurred during the study. Four SAEs were reported in the revaccination group. Two of these events (mild pyrexia on Day 2 postvaccination; severe herpes virus infection on Day 7 postvaccination) were assessed as vaccine-related AEs by the study investigators.
Discussion
Our study demonstrated that serotype-specific IgG GMCs to serotypes 3, 6B, and 23F measured at 4 weeks after revaccination with PPSV23 were significantly higher than those measured immediately before revaccination. Increases in IgG GMCs from baseline to postvaccination were also observed for 11 additional vaccine serotypes that were tested by Pn ECL assay in this study. In addition to IgG responses, several studies have emphasized the need to measure functional OPA antibodies as an important biolog- ical marker for the prevention of pneumococcal disease, especially in the elderly [20, 21] . Results from our study showed that serotype-specific OPA GMTs for 6 vaccine serotypes were higher at 4 weeks after revaccination than immediately before PPSV23 revaccination. IgG and OPA fold-rises for all serotypes were significantly lower following revaccination than primary vaccination with PPSV23 (nominal P < 0.05). This is likely due to the presence of pre-existing anti-pneumococcal antibodies and is consistent with previous findings [12, 14] . To our knowledge, our study is the first study that has measured IgG concentrations for serotype 22F, and 33F and OPA titer for serotype 22F following receipt of a second dose of PPSV23 in the elderly Japanese individuals. Of interest is the increase in both IgG GMC and OPA GMT to serotype 3, as it has been identified as the most common cause of IPD in Japanese adults [11] . Although serotype 6A is not contained in PPSV23, IgG GMC for serotype 6A increased following vaccination with PPSV23 in both groups, which indicates possible cross-protection afforded by serotype 6B included in PPSV23 against pneumococcal disease caused by serotype 6A.
The matching of subjects' key baseline characteristics (i.e. age, gender, and underlying medical conditions) between the primary and revaccination groups were performed so as to evaluate the serotype-specific immune responses as well as safety in both vaccination groups excluding the potential factors associated with the immune responses [22, 23] . Although not superior to levels achieved after primary vaccination, immune responses increased from baseline to postvaccination after a second dose of PPSV23 administered at least 5 years after the initial dose, and the magnitude of the elicited IgG concentrations and OPA titers reached levels comparable to those observed in the primary vaccination group. Though immune responses after the second dose of PPSV23 are reported to be lower than those observed after the initial dose in another study [24] , no evidence of hyporesponsiveness following PPSV23 revaccination was observed for the serotypes evaluated in our study. The analyses of subgroups by comorbidities in the revaccination group suggest that baseline serotype-specific IgG GMCs were not affected by the presence of underlying comorbidities; however baseline serotype-specific OPA titers for serotypes 6B, 14, and 22F in subjects with comorbidities (chronic heart disease, chronic lung disease, and diabetes mellitus) tended to be lower than those in subjects without comorbidities (supplementary data, Tables S1
and S3, Figs. S1A and S2A). Increases in IgG GMCs and OPA GMTs after revaccination with PPSV23 were also observed in subjects with comorbidities (supplementary data, Tables S2 and S4, Figs. S1B and S2B). This observation is consistent with the report in the Japanese elderly patients with chronic lung disease [17] . Therefore, we demonstrated that revaccination with PPSV23 in elderly subjects could induce the immune responses regardless of comorbidities such as chronic heart disease, chronic lung disease, and diabetes mellitus.
The analyses of subgroups by age in the revaccination group showed no differences in baseline IgG GMCs and OPA GMTs between subjects aged 70-79 years and subjects aged 80-89 years. Revaccination with PPSV23 in both subgroups led to comparable increases in serotype-specific IgG GMCs and OPA GMTs for all serotypes tested (supplementary data, Tables S5 and S6, Fig. S3 ). These data suggest that revaccination with PPSV23 at least 5 years No deaths or discontinuation due to vaccine-related severe adverse events. AE, adverse event; PPSV23, 23-valent pneumococcal polysaccharide vaccine; CI, confidence interval. The size of injection-site erythema and swelling were measured by inch. The inch unit were converted to the centimeter (cm).
after the initial dose induces satisfactory immune responses even in older Japanese adults. The safety analysis showed that the incidence of injection-site AEs was significantly higher in the revaccination group than in the primary vaccination group. However, most AEs were mild to moderate in intensity, and resolved within 5 days of onset without any medical treatment. Incidence rates of systemic AEs were comparable in the revaccination and primary vaccination groups. Our study results are consistent with those observed in previous studies evaluating safety following revaccination with PPSV23 [12, 17, 25] .
Although enrolling more subjects than previous studies of PPSV23 revaccination in the Japanese elderly, the sample size of our study was still limited to 161 revaccinated subjects, and serotype-specific antibodies were measured only for a subset of vaccine serotypes, 14 serotypes for IgG GMCs and 6 serotypes for OPA GMTs. The clinical benefits of the observed increases in antibody levels following primary or revaccination with PPSV23 cannot be clearly established, as thresholds of serotype-specific antibody concentrations and OPA titers that correlate with prevention of pneumococcal disease in adults have not been established. Additional studies on the relationship between levels of vaccineinduced antibodies achieved following revaccination with PPSV23 and prevention of pneumococcal disease need further evaluation.
Conclusions
The results of the present study showed that revaccination with PPSV23 was well tolerated and associated with an increase in IgG concentrations and OPA titers in the Japanese elderly P70 years of age who had received PPSV23 at least 5 years before. The levels of serotype-specific IgG GMCs and OPA GMTs measured in revaccinated subjects were generally comparable to those observed following primary vaccination for the serotypes tested. Currently, Japan has a rapidly growing elderly population, wherein 1 in 5 people are aged P70 years. The findings of the present study are important clinical evidence that a second dose of PPSV23 can be safely administered and elicit favorable immune responses for the continued prevention of pneumococcal disease in the elderly population.
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